interleukin-2-activated umbilical cord blood cells

Interleukin-2-activated umbilical cord blood cells are an experimental cellular immunotherapy consisting of mononuclear cells (MNCs) derived from human umbilical cord blood that have been activated ex vivo with the cytokine interleukin-2 (IL-2). This activation process induces the differentiation and expansion of potent effector cells, primarily CD56+ natural killer (NK) cells and lymphocyte-activated killer (LAK) cells. These activated cells exhibit significantly enhanced antitumor cytotoxic activity compared to non-activated cord blood cells. The therapeutic effect is primarily mediated through two pathways: the calcium-dependent perforin/granzyme-mediated cytolysis and the Fas ligand (FasL)-mediated apoptotic pathway. Preclinical research has demonstrated significant in vitro and in vivo efficacy against various malignancies, including hematological cancers such as leukemia and lymphoma, as well as solid tumors like breast cancer and neuroblastoma. Currently, this approach is primarily studied in academic research settings and has not been developed into a commercial drug product with a specific brand name.

Other names

IL-2-activated UCBCsIL2-activated UCBCsIL 2-activated UCBCsIL-2-activated umbilical cord blood mononuclear cellsIL2-activated umbilical cord blood mononuclear cellsIL 2-activated umbilical cord blood mononuclear cellsactivated cord blood cellsinterleukin-2-activated umbilical cord blood mononuclear cellsinterleukin2-activated umbilical cord blood mononuclear cellsinterleukin 2-activated umbilical cord blood mononuclear cells